Design, Synthesis, Antimicrobial Evaluation, Antioxidant Studies, and Molecular Docking of Some New 1H‐Benzimidazole Derivatives

Abstract

The goal of this study is to synthesize and test a series of novel benzimidazole derivatives (3 a–3 q, 4 a, 4 b) for antimicrobial and antioxidant activity. The compounds were tested for antimicrobial activity in vitro using the macro dilution broth method. The antioxidant activity of the synthesized compounds was evaluated using assay of Lipid peroxidation (LP) level by measuring the formation of 2‐thiobarbituric acid reactive substances (TBARS) and 7‐Ethoxyresorufin O‐deethylase (EROD) activity. Only the compound 3 m demonstrated significant antimicrobial activity against all of the microorganisms tested. The LP level of compound 3 m (5.20±0.28, 68 %) was comparable to that of standard BHT (5.68±0.22, 65 %). Compounds 3 i (11 %, 28 %) and 3 m (13 %, 32 %) are the most active compounds on microsomal EROD activity and LP levels which are better than standard caffeine (15 %) and BHT (35 %), respectively. Also compounds 3 g (20 %), and 4 b (28 %) have much better LP levels than BHT (35 %). Compound 3 m exhibited high docking energies scores comparing with reference drugs when docked with bacterial Penicillin‐Binding Protein 3 and 4, sterol 14 α‐demethylase of C. albicans and urate oxidase enzyme.

Synthesis, DFT Calculations, In Silico Studies, and Antimicrobial Evaluation of Benzimidazole-Thiadiazole Derivatives

“…14 A variety of 1,3,4-thiadiazole is in use, like Acetazolamide (diuretic), Cefazolin, Cefazedone (antibiotics), Megazol (antiprotozoal), Timolol maleate (NSAIDs), Methazolamide (carbonic anhydrase inhibitor), and Sulphamethizole (antibacterial). 15 This article is licensed under CC-BY 4 In this study, a new series of benzimidazole-thiadiazole derivatives were synthesized and characterized by 1 H NMR, 13 C NMR, and HRMS. Synthesized compounds were screened for their antimicrobial activities against eight species of pathogenic bacteria [Escherichia coli (ATCC 25 922), Serratia marcescens (ATCC 8100), Klebsiella pneumoniae (ATCC 13 883), Pseudomonas aeruginosa (ATCC 27 853), Enterococcus faecalis (ATCC 2942), Bacillus subtilis, Staphylococcus.…”

“…Microbial resistance is one of the most burning problems in clinical practice, and one of the main objectives of current biomedical research is to discover new, powerful drugs that can combat multiresistant bacteria. Antibiotic abuse and pharmaceutical corporations’ lack of interest in investing in antibiotic development has made the discovery of new antibiotic classess inevitable. − …”

“…Antibiotic abuse and pharmaceutical corporations’ lack of interest in investing in antibiotic development has made the discovery of new antibiotic classess inevitable. 2 − 4 …”